T7947
（R）-托莫西汀 盐酸盐
solid
别名:
盐酸托莫西汀 盐酸盐, （R）-N-甲基-γ-（2-甲基苯氧基）苯丙胺 盐酸盐
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H21NO · HCl
化学文摘社编号:
分子量:
291.82
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
表单
solid
质量水平
创始人
Eli Lilly
储存温度
2-8°C
SMILES字符串
CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl
InChI
1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
InChI key
LUCXVPAZUDVVBT-UNTBIKODSA-N
基因信息
human ... SLC6A2(6530)
正在寻找类似产品? 访问 产品对比指南
相关类别
应用
(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:
- to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice
- to study its effects on set shifting in rats
- to study its effects on rat brain as a result of its long-term use
生化/生理作用
去甲肾上腺素摄取阻滞剂。
(R)-Tomoxetine hydrochloride is an efficient inhibitor of presynaptic norepinephrine transporters. It also positively regulates the release of acetylcholine in the prefrontal cortex (PFC). (R)-Tomoxetine hydrochloride binds to the serotonin (5-HT) transporter. It is involved in blocking the cortical N-methyl-D-aspartate (NMDA) receptors.. (R)-Tomoxetine hydrochloride exhibits therapeutic effects against attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).
特点和优势
This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Fatma Gür et al.
Biochemical and biophysical research communications, 534, 927-932 (2020-11-05)
Attention Deficit Hyperactivity Disorder (ADHD) is the most common psychiatric disorder reported particularly in children. Long-term use of antipsychotic drugs used in the treatment of ADHD has been shown to exert toxic effects on the brain. However, not enough research
Grazia Dell'Agnello et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 19(11), 822-834 (2009-09-01)
The primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support. This was
George Bush et al.
Psychiatry research, 211(1), 88-91 (2012-11-14)
We hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-deficit/hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults performed the Multi-Source Interference Task (MSIT) during functional magnetic resonance imaging (fMRI) at baseline and after 6 weeks
Todd M Durell et al.
Journal of clinical psychopharmacology, 33(1), 45-54 (2013-01-02)
Attention-deficit/hyperactivity disorder (ADHD) is associated with significant impairment in multiple functional domains. This trial evaluated efficacy in ADHD symptoms and functional outcomes in young adults treated with atomoxetine. Young adults (18-30 years old) with ADHD were randomized to 12 weeks
Nora D Volkow et al.
The New England journal of medicine, 369(20), 1935-1944 (2013-11-15)
Short-term trials involving adults with ADHD have shown significant improvements in symptoms with stimulants and atomoxetine; however, data on long-term benefits and risks of these medications, particularly among older persons, have been insufficient.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持